Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

被引：0
|
作者：
C. McArthur
C. Daruwalla
M. Jayeskara
J. W. L. Brown
机构：
[1] University of East Anglia,Norwich Medical School
[2] University of Cambridge,Department of Clinical Neurosciences
来源：
Journal of Neurology | 2023年 / 270卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5127 / 5129
页数：2
相关论文
共 50 条
  • [41] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
    Trojano, Maria
    Paolicelli, Damiano
    Fuiani, Aurora
    Pellegrini, Fabio
    Iaffaldano, Pietro
    Direnzo, Vita
    D'Onghia, Mariangela
    NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) : S225 - S226
  • [42] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
    Maria Trojano
    Damiano Paolicelli
    Aurora Fuiani
    Fabio Pellegrini
    Pietro Iaffaldano
    Vita Direnzo
    Mariangela D’Onghia
    Neurological Sciences, 2008, 29 : 225 - 226
  • [43] Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence
    Cole, M.
    Le, H.
    Verma, S.
    Keenan, A.
    Leist, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 92 - 92
  • [44] Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
    Zanghi, Aurora
    D'Amico, Emanuele
    Callari, Graziella
    Chisari, Clara Grazia
    Borriello, Giovanna
    Grimaldi, Luigi Maria Edoardo
    Patti, Francesco
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [45] Real-World Assessment of Adherence and Persistence to Second-Line Disease-Modifying Therapies among Multiple Sclerosis Patients
    Halpern, Rachel
    Agarwal, Sonalee
    Borton, Leigh A.
    Babic, Tomislav
    NEUROLOGY, 2010, 74 (09) : A548 - A549
  • [46] Analysis of oral disease-modifying therapies using real-world data from the German NeuroTransData multiple sclerosis registry
    Braune, Stefan
    Heer, Yannic
    Jarecki, Jana
    Zurcher, Mel
    DeBoer, Erik
    Wisskirchen, Christian
    Biswas, Mousumi
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1019 - 1019
  • [47] Real-world effectiveness of initial treatment with newer versus injectable disease-modifying therapies in pediatric multiple sclerosis in the US
    Krysko, K. M.
    Graves, J. S.
    Rensel, M.
    Weinstock-Guttman, B.
    Rutatangwa, A.
    Aaen, G.
    Benson, L.
    Chitnis, T.
    Gorman, M.
    Goyal, M.
    Harris, Y.
    Krupp, L.
    Lotze, T.
    Mar, S.
    Moodley, M.
    Rodriguez, M.
    Rose, J.
    Schreiner, T.
    Waltz, M.
    Casper, T. C.
    Waubant, E.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 97 - 98
  • [48] A Real-World Study of Disease-Modifying Drug Treatment Patterns in US Patients with Multiple Sclerosis Newly Initiating Treatment
    Nicholas, Jacqueline
    Edwards, Natalie C.
    Harlow, Danielle
    Phillips, Amy
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 20 - 20
  • [49] Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients
    Gloria Dalla Costa
    Annamaria Finardi
    Livia Garzetti
    Tiziana Carandini
    Giancarlo Comi
    Vittorio Martinelli
    Roberto Furlan
    Neurological Sciences, 2018, 39 : 373 - 376
  • [50] Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
    Lebrun, Christine
    Debouverie, Marc
    Vermersch, Patrick
    Clavelou, Pierre
    Rumbach, Lucien
    de Seze, Jerome
    Wiertlevski, Sandrine
    Defer, Gilles
    Gout, Olivier
    Berthier, Frederic
    Danzon, Arlette
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (03) : 399 - 405
12345